MX2019009500A - Anticuerpos anti factor de coagulación xi. - Google Patents
Anticuerpos anti factor de coagulación xi.Info
- Publication number
- MX2019009500A MX2019009500A MX2019009500A MX2019009500A MX2019009500A MX 2019009500 A MX2019009500 A MX 2019009500A MX 2019009500 A MX2019009500 A MX 2019009500A MX 2019009500 A MX2019009500 A MX 2019009500A MX 2019009500 A MX2019009500 A MX 2019009500A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- coagulation factor
- fxia
- fxi
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710073984.XA CN108409863B (zh) | 2017-02-10 | 2017-02-10 | 抗凝血因子xi抗体 |
| PCT/CN2017/119856 WO2018145533A1 (zh) | 2017-02-10 | 2017-12-29 | 抗凝血因子xi抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009500A true MX2019009500A (es) | 2020-01-30 |
Family
ID=63107934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009500A MX2019009500A (es) | 2017-02-10 | 2017-12-29 | Anticuerpos anti factor de coagulación xi. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3581587B1 (enExample) |
| JP (1) | JP7271430B2 (enExample) |
| KR (1) | KR102690437B1 (enExample) |
| CN (1) | CN108409863B (enExample) |
| AU (2) | AU2017397778B2 (enExample) |
| BR (1) | BR112019016300A2 (enExample) |
| CA (1) | CA3054322A1 (enExample) |
| MX (1) | MX2019009500A (enExample) |
| WO (1) | WO2018145533A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11958911B2 (en) | 2017-02-10 | 2024-04-16 | Shanghai Benemae Pharmaceutical | Anti-coagulation factor XI antibody |
| WO2020029179A1 (en) * | 2018-08-09 | 2020-02-13 | Shanghai Benemae Pharmaceutical Corporation | Anti-factor xi antibodies |
| CN110878123B (zh) | 2018-09-05 | 2022-08-23 | 华瑞同康生物技术（深圳）有限公司 | 一种抗tk1原核重组单链抗体及制备方法 |
| JP7509787B2 (ja) * | 2019-01-21 | 2024-07-02 | アロノラ・インコーポレイテッド | 抗血栓症作用および抗炎症作用を有する、第ｘｉ因子に対する新規ヒト化抗体およびその使用 |
| WO2020211674A1 (zh) * | 2019-04-16 | 2020-10-22 | 四川科伦博泰生物医药股份有限公司 | 抗FXI/FXIa抗体及其用途 |
| CN110423278B (zh) * | 2019-08-08 | 2020-07-17 | 上海博槿生物科技有限公司 | 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用 |
| CN110498839A (zh) * | 2019-09-19 | 2019-11-26 | 河南省农业科学院 | 氟罗沙星单链抗体关键多肽序列及应用 |
| JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
| KR20230034361A (ko) * | 2020-07-02 | 2023-03-09 | 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 | 항-fxi/fxia 항체, 이의 항원-결합 단편, 및 이의 약제학적 용도 |
| CN116589588B (zh) * | 2023-04-14 | 2023-12-22 | 北京基科晟斯医药科技有限公司 | 结合凝血因子x的抗体 |
| WO2025130748A1 (zh) * | 2023-12-22 | 2025-06-26 | 四川科伦博泰生物医药股份有限公司 | 一种抗凝血因子XI/XIa抗体制剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2981754B2 (ja) * | 1990-02-02 | 1999-11-22 | 第一化学薬品株式会社 | 血液凝固第▲ｘ▼▲ｉｉｉ▼因子に対するモノクロナール抗体 |
| DE60230037D1 (de) * | 2001-06-12 | 2009-01-08 | Chemo Sero Therapeut Res Inst | Humanantikörper gegen blutgerinnungsfaktor viii |
| DE10205520A1 (de) * | 2002-02-08 | 2003-08-14 | Aventis Behring Gmbh | Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease |
| ES2566963T3 (es) * | 2007-11-21 | 2016-04-18 | Oregon Health & Science University | Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos |
| LT2373691T (lt) * | 2008-12-18 | 2019-05-27 | Oregon Health & Science University | Anti-fxi antikūnai ir jų panaudojimo būdai |
| BR112014027952B1 (pt) * | 2012-05-10 | 2022-06-21 | Bayer Pharma Aktiengesellschaft | Anticorpos monoclonais humanos capazes de se ligarem ao fator de coagulação xi, seu uso, composição farmacêutica e medicamento os compreendendo, ácido nucleico que o codifica, bem como vetor |
| UY36751A (es) * | 2015-06-26 | 2017-01-31 | Novartis Ag | Anticuerpos de factor xi y métodos de uso |
| US11066481B2 (en) * | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
-
2017
- 2017-02-10 CN CN201710073984.XA patent/CN108409863B/zh active Active
- 2017-12-29 CA CA3054322A patent/CA3054322A1/en active Pending
- 2017-12-29 JP JP2019543277A patent/JP7271430B2/ja active Active
- 2017-12-29 KR KR1020197025752A patent/KR102690437B1/ko active Active
- 2017-12-29 AU AU2017397778A patent/AU2017397778B2/en active Active
- 2017-12-29 MX MX2019009500A patent/MX2019009500A/es unknown
- 2017-12-29 BR BR112019016300-0A patent/BR112019016300A2/pt unknown
- 2017-12-29 EP EP17895532.4A patent/EP3581587B1/en active Active
- 2017-12-29 WO PCT/CN2017/119856 patent/WO2018145533A1/zh not_active Ceased
-
2025
- 2025-05-08 AU AU2025203303A patent/AU2025203303A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN108409863A (zh) | 2018-08-17 |
| KR20190116990A (ko) | 2019-10-15 |
| AU2025203303A1 (en) | 2025-05-29 |
| CA3054322A1 (en) | 2018-08-16 |
| AU2017397778A1 (en) | 2019-10-03 |
| EP3581587B1 (en) | 2025-02-05 |
| RU2019128423A3 (enExample) | 2021-03-19 |
| AU2017397778B2 (en) | 2025-03-06 |
| CN108409863B (zh) | 2023-09-26 |
| KR102690437B1 (ko) | 2024-07-30 |
| BR112019016300A2 (pt) | 2020-06-16 |
| JP2020507578A (ja) | 2020-03-12 |
| JP7271430B2 (ja) | 2023-05-11 |
| RU2019128423A (ru) | 2021-03-10 |
| EP3581587A1 (en) | 2019-12-18 |
| WO2018145533A1 (zh) | 2018-08-16 |
| EP3581587A4 (en) | 2021-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018005720A (es) | Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello. | |
| WO2018089508A3 (en) | Anti-cd47 antibodies | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
| WO2018031490A3 (en) | Anti-ox40 binding proteins | |
| EP3486256A3 (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
| MY186711A (en) | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer | |
| MY192532A (en) | Liquid pharmaceutical composition | |
| MX2016011295A (es) | Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2. | |
| PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
| HK1255056A1 (zh) | 抗cd115抗体 | |
| MX2021001613A (es) | Anticuerpos anti-factor xi. | |
| BR112019016300A2 (pt) | ANTICORPO ANTI-FXI OU ANTI-FXIa ISOLADO, SEU USO E MÉTODO DE PREPARAÇÃO, COMPOSIÇÃO FARMACÊUTICA E ANTICORPO OU UM FRAGMENTO FUNCIONAL DO MESMO OU UMA PORÇÃO IMUNOLOGICAMENTE ATIVA DO MESMO | |
| HK1259083A1 (zh) | 用於治疗系统性肥大细胞增多症的方法和组合物 | |
| ZA201900070B (en) | Antibodies with low immunogenicity and uses thereof | |
| MX2022015959A (es) | Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
| MX2015008310A (es) | Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -. | |
| WO2018097712A8 (en) | PROCESS FOR PREPARING A GLUCIDIC AND / OR PROTEIN PRODUCT | |
| MX2018009264A (es) | Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos. | |
| EP4089109A3 (en) | Methods for preparing modified von willebrand factor | |
| MX2016010852A (es) | Anticuerpo anti-inhibidor de activador de plasminogeno 1 (pai-1) humano novedoso. | |
| WO2017062682A8 (en) | Method for treating multiple sclerosis | |
| PH12018501277A1 (en) | Corticosteroid containing foam compositions and method of manufacture thereof | |
| SG11201907914QA (en) | Polypeptide, polypeptide fragment, derivative thereof, and applications thereof |